Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment

BACKGROUND: The purpose of this study was to determine whether adding the anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to carboplatin/paclitaxel improved pathologic complete response (pCR) at reassessment surgery in epithelial ovarian, fallopian tube, or primary p...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Blank, Stephanie V., Christos, Paul, Curtin, John P., Goldman, Noah, Runowicz, Carolyn D., Sparano, Joseph A., Liebes, Leonard, Chen, Helen X., Muggia, Franco M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2010
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3446254/
https://ncbi.nlm.nih.gov/pubmed/20837357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2010.08.008
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky